Christen S, Redeuil K, Goulet L, Giner MP, Breton I, Rota R, et al
Bisubstrate strategies to target methyltransferases
A 5 mg vial contains 5,000 mcg
Results Liraglutide does not alter behavioural markers of ALS in a TDP-43 Q331K model of ALS TDP-43 Q331K transgenic female mice were dosed IP daily with vehicle or 25 nmol/kg liraglutide from 25 to 180 days of age
Patients with coexisting diabetes or obesity and Crohn's disease require careful coordination between specialists, as GLP-1 agonists' gastrointestinal side effects overlap significantly with IBD symptoms, potentially complicating disease monitoring and management
b , Oral glucose tolerance testing (OGTT) was performed and the AUCs were calculated